Reputations for Sale ? BMJ-BBC-Panorama-Seroxat/ Paxil
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
"Daily use of SSRIs was also associated with a four per cent reduction in bone mineral density of the hip and 2.4 per cent of the lower spine, the study found."
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
Eli Lilly Prozac Documents: What do They Reveal? Thu, 27 Jan 2005 A report in the BMJ (formerly the British Medical Journal) that relied on internal Eli Lilly documents to challenge Lilly’s claims about the safety of Prozac has stirred a prickly hornet’s nest. [1] The documents show, among other…
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior…
Evidence of Antidepressant Harm that the FDA Sought to Suppress from FDA’s Public Advisory Committee Meeting on February 2 Evidence was presented on February 2 at AHRP’s press briefing by the following scientists: David Healy, MD, Director of the North Wales Department of Psychological Medicine and Visiting Professor, University of…
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…